Arrowpoint Investment Partners’s Capricor Therapeutics CAPR Stock Holding History

Arrowpoint Investment Partners’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$225K	Buy	+9,342	New	+$283K	0.05%	104

Other funds holding CAPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Arrowpoint Investment Partners's CAPR Position: Q2 2026 in Review

Arrowpoint Investment Partners opened a new position in Capricor Therapeutics (CAPR) in Q2 2026: 9,342 shares worth $225K. The stake represents 0.05% of the portfolio and ranks #104 among its holdings.

170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

Arrowpoint Investment Partners held 9,342 shares of Capricor Therapeutics worth $225K as of Q2 2026.
Capricor Therapeutics was a new Arrowpoint Investment Partners position in Q2 2026.
Capricor Therapeutics made up 0.05% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #104 holding.
170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.